Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States |
| gptkbp:ATCCode |
D11AH10
|
| gptkbp:brand |
EBGLYSS
LEBRIKIZUMAB |
| gptkbp:CASNumber |
1197996-61-6
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
gptkb:Dermira |
| https://www.w3.org/2000/01/rdf-schema#label |
lebrikizumab
|
| gptkbp:indication |
moderate-to-severe atopic dermatitis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
blocks IL-13 signaling
|
| gptkbp:PubChem_CID |
gptkb:DB12161
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
injection site reaction
conjunctivitis upper respiratory tract infection |
| gptkbp:target |
gptkb:interleukin-13
|
| gptkbp:UNII |
6F1A1Y9FZ7
|
| gptkbp:usedFor |
gptkb:atopic_dermatitis
|
| gptkbp:bfsParent |
gptkb:IL-13
gptkb:Interleukin_13 gptkb:interleukin-13 gptkb:interleukin-13_protein |
| gptkbp:bfsLayer |
7
|